Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Papillomavirus Infections 11Warts 2Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 2HIV Infections 2Condylomata Acuminata 2Acquired Immunodeficiency Syndrome 2Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Infections 1Human Papillomavirus-Related Cervical Carcinoma 1Human Papillomavirus-Related Carcinoma 1High Grade Anal Canal Intraepithelial Neoplasia 1Hematologic Neoplasms 1Cancer Survivor 1

Interventions

Educational Status 3Methods 2Early Intervention, Educational 2Vaccines, Synthetic 1Transcranial Magnetic Stimulation 1Standard of Care 1Human Papillomavirus Recombinant Vaccine nonavalent 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Exercise 1Diet Therapy 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cancer Survivor × Human Papillomavirus Recombinant Vaccine nonavalent × Clear all
NCT01492582 2021-10-27

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

University of Alabama at Birmingham

Phase 2 Completed
1,499 enrolled 11 charts

Cancer Survivor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡